Tranexamic Acid Use and Post Operative Outcome in Patients Undergoing Spine Surgery for Scoliosis in An-Najah National University Hospital / Palestine: A Prospective, Randomized, Double Blinded Study

Abstract

Context: Some reports have been published regarding the effectiveness of Tranexamic acid (TXA) on reducing blood loss and blood transfusion in patients undergoing orthopedic and major orthopedic surgery. We performed a prospective randomized control study to evaluate the effectiveness and safety of preoperative tranexamic acid use on blood transfusion, thromboembolic events and mortality in patients undergoing spinal surgery for scoliosis in An-Najah National University Hospital in Palestine.

Materials and Methods: A prospective, randomized, double blinded study was conducted in the tertiary care teaching hospital. The weighted mean difference in blood loss, number of transfusions per patient, and the risk ratio of transfusion and deep vein thrombosis (DVT) were calculated in the tranexamic acid (TXA) treated group and the control group.

Hundred ASA grade 1-11 patients undergoing spinal surgery for scoliosis were included in this prospective study. Fifty patients received Tranexamic acid (TXA) given in a bolus dose of 10 mg/kg 15 minutes before surgical incision followed by 10 mg/kg every 3 hours. The remaining fifty patients were allocated as a control group. Postoperative bleeding (volume of blood in the drain), percentage fall of hemoglobin, transfusions and postoperative complications were recorded.

Results: Mean volume of blood in the drain was 940 ± 495 ml (mean ± SD) as compared to 1450 ± 740 ml in placebo group showing a p<0.001. Mean percentage fall in Hb at day 0 was 3.2 ± 2.1 in the study group as compared to 8.8 ± 3.0 in the placebo group (p<0.001), and fall at day two in the study group was 1.1 ± 0.4 compared to 3.8 ± 2.7 in the placebo group (p<0.001). The number of patients required blood transfusions were lower in the study group than in placebo group (p=0.01).

Conclusion: Tranexamic acid significantly reduces postoperative blood loss and blood transfusion requirements during spinal surgery for scoliosis correction.

Keywords: Tranexamic acid; Blood transfusion; Postoperative bleeding

Received: April 15, 2015; Accepted: November 19, 2015; Published: November 28, 2015
Introduction

Reducing blood loss and the need of blood transfusions in spinal surgery remains a major concern among clinicians during the preoperative period. Many interventions have been developed over the past decades to achieve this goal, including controlled hypertensive anesthesia, and various blood salvage techniques. In addition, pharmacologic approaches have become more popular in recent years. Especially, tranexamic acid has seen a renaissance among patients requiring scoliosis surgery, with numerous publications showing clinical efficacy and cost effectiveness. Indeed a recent study found that the use of tranexamic acid may even make the use of blood salvage equipment unnecessary. Despite these promising results, valid data on safety are lacking, as large sample sizes are needed to determine this outcome. Thus concerns about the routine use of tranexamic acid remain.

Data on preoperative outcomes, especially those related to thromboembolic events and renal complications, which have traditionally been of concern in the setting of antifibrinolytic use, are rare. Further, no population based data were available detailing outcomes in a large cohort outside of randomized controlled trials, which often only include selected patients based on stringent inclusion criteria and are thus not reflective of real world practice and are burdened by low external validity.

Utilizing the hospital database, we compared the characteristics and outcomes between patients receiving tranexamic acid and those that did not and analyzed if the use of tranexamic acid is independently associated with altered odds for blood transfusions and preoperative complications, particularly thromboembolic events and acute renal failure. We hypothesized that the characteristics associated with treated and untreated patients differed, and that tranexamic acid decreases the odds for blood transfusions while not increasing the risk of preoperative complications [1-10].

Methods

Hundred patients (ASA grade 1/11 patients between the age of 6 and 15 years, weighing 20-60 kg) undergoing spinal surgery for scoliosis, from 01/05/2013 to 03/04/2014. Patients with chronic disease like rheumatoid arthritis, malignancy, history of any previous thromboembolic episodes, hemoglobin <8 g/dl were excluded from the study. The study was approved by the institutional Ethics committee and written informed consent was obtained from each patient.

They were allocated to two groups. Randomization was done by opaque sealed envelope technique.

Group T: patients received injection. TXA 10 mg/kg body weight.

Group P: patients received physiological saline 1 ml/kg body weight.

Preoperatively, the hemoglobin concentration, bleeding time, clotting times were measured on the day before operation. All patients in the study group received a bolus intravenous injection of 1 mg/kg TXA is 50 ml syringe during 10 minutes, about 15 minutes before surgery, and the same dose is repeated every three hours until the surgery is completed patients in the placebo group received normal saline a bolus intravenous injection of 50 ml about 15 minutes before surgery followed by continuous infusion of saline until the surgery is completed. Drug and normal saline were loaded by an independent anesthetist.

Surgery was performed under general anesthesia with Fentanyl 1 mcg/kg ,Midazolam 25 mcg/kg, Propofol 2 mg /kg and Tracrium 0.5 mg/kg , during induction and Sevoflurane 2.6% in oxygen, Remifentanil I/V 0.5 mcg/kg/minute I/V infusion and Propofol I/V infusion 0.1 mg/kg/minute during maintenance.

Hemodynamic (hear rate, systolic, diastolic, mean arterial blood pressure) was noted through the arterial line starting from preoperative to the second day of surgery. Ringer’s solution was used as the replacement fluid for the estimated intrathecal blood volume lost 3:1 ratio.

There was no significant difference in amount of fluid in both groups. Postoperative hemoglobin concentration (on day 0 and day 2) and volume of blood in the drain when the patient entered into the recovery room on the day of operation were measured. The number of units of packed red cells transfused during the hospital stay was recorded, and any thromboembolic and other complication were documented. A criterion for blood transfusion was a reduction in hemoglobin exceeding 25% of preoperative level.

For tests of differences between quantitative data, two sided paired difference tests were used. In the text, data presented as mean ± standard deviation (SD) and p <0.05 are considered significant. The data was analyzed by SPSS [11-17].

Results

There were no significant difference between the patients with respect to age, sex, duration and type of surgery and preoperative mean hemoglobin concentration. Neither heart rate nor mean arterial blood pressure (MABP) has statistically significant difference or results (p>0.05). As shown in Table 1 and Figures 1&2.

The drains were removed in the morning of the third postoperative day. Mean volume of blood in the drain was 940. ± 495 ml (mean ± SD) as compared to 1450 ± 740 ml in placebo group showing (p<0.001) showing a highly significant reduction of postoperative blood loss (Figure 2).

Mean volume of the blood in day 0 was 430 ml in placebo group compared to 290 ml in study group and in day two 180 ml in placebo group vs. 90 ml in study group.

Mean percentage fall in Hb at day 0 was 8.5 g in the study group as compared to 6.5 g in the placebo group (p<0.197) making it significant finding (Figure 3). Fall of hemoglobin at day two in the study group was 3.8 g compared to 1.1 g in the placebo group (p<0.001).

Table 1 Patient characteristics, laboratory and surgical data.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Placebo (n=50)</th>
<th>Study (n=50)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>10.1 ± 6.2</td>
<td>11.2 ± 5.3</td>
<td>0.9</td>
</tr>
<tr>
<td>Sex M/F</td>
<td>30/20</td>
<td>30/20</td>
<td>NA</td>
</tr>
<tr>
<td>Duration of surgery (min)</td>
<td>300.7 ± 12.3</td>
<td>285 ± 10.7</td>
<td>0.5</td>
</tr>
<tr>
<td>Preoperative hemoglobin</td>
<td>11.2 ± 1.3</td>
<td>11.1 ± 1.3</td>
<td>0.2</td>
</tr>
</tbody>
</table>
In our study out of fifty patients, 32 patients who fell in the placebo group required blood transfusion, while 13 patients out of 50 in the study group needed a transfusion (p<0.01). No significant complications like thromboembolic episodes were encountered in both groups Table 2.

This was indicated by volume of blood in the drain and fall in the hemoglobin postoperatively.

A similar study was conducted by Sadeghi and Mehraein to see the effect of TXA on hip fracture surgery. They found preoperative blood loss significantly lower in TXA group (p<0.03). The total blood loss was 960 ± 483 ml in TXA group and 1484 ± 724 ml in the control group (p<0.001). Postoperative drainage was lower in TXA group (296 ± 85ml vs. 475 ± 110 ml, p<0.195). There were no difference in coagulation parameters. The rate of transfused patients in TXA group 37% and 57% in the control group.

Table 2

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Placebo</th>
<th>Study</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume of blood in drain</td>
<td>1450 ± 740 ml</td>
<td>940 ± 495 ml</td>
<td>0.001</td>
</tr>
<tr>
<td>Day 0</td>
<td>420 ± 130 ml</td>
<td>290 ± 90 ml</td>
<td>0.197</td>
</tr>
<tr>
<td>Day 2</td>
<td>180 ± 90 ml</td>
<td>90 ± 50 ml</td>
<td>0.001</td>
</tr>
<tr>
<td>Day 3</td>
<td>120 ± 10 ml</td>
<td>50 ± 8 ml</td>
<td>0.000</td>
</tr>
<tr>
<td>Postoperative Hb concentration</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 0</td>
<td>8.5 ± 0.8</td>
<td>6.5 ± 0.5</td>
<td></td>
</tr>
<tr>
<td>Day 2</td>
<td>9.1 ± 0.5</td>
<td>02.1 ± 0.6</td>
<td></td>
</tr>
<tr>
<td>Percentage fall of Hb at day 0 from base line</td>
<td>8.8 ± 3.0</td>
<td>3.2 ± 2.1</td>
<td>0.00</td>
</tr>
<tr>
<td>Percentage fall of Hb at day 2 from day 0</td>
<td>3.8 ± 2.7</td>
<td>1.1 ± 0.4</td>
<td>0.00</td>
</tr>
</tbody>
</table>

This was indicated by volume of blood in the drain and fall in the hemoglobin postoperatively.

Other studies Benoni et al., [18] Jansen et al., [19] Yamasaki et al., [20] Ekback et al., [21] and Sano et al., [22] was conducted on THR or TKR. The volume of blood loss in the procedures may be lesser or greater than during hip fracture surgery and can be attributed to duration as well procedure, but still results were not dissimilar with our study. Benoni et al administered TXA intravenously before tourniquet release and than 3 hours later in patients undergoing TKR, and reported that the intra and postoperative blood loss were reduced to one –third as a result. However in contrast to elective hip or knee surgery, in hip fracture, the fibrinolytic system is activated by trauma and increased during surgery. so we used a single bolus dose of TXA 15 minutes before the incision followed by the same dose every 3 hours to insure that its clot stabilize the effect would cover the intra and postoperative period.

In agreement with our finding , which were based on a surgical procedure that was of similar duration ≥ 120 minute Ekback et al. [21] showed that the preoperative blood loss was significantly lower in the TXA treated group than the control group, postoperative drainage bleeding was correspondingly less (p=0.001) ( 520 ± 280 vs. 920 ± 410 ml).

Jansen et al investigated the effect of TXA on blood loss in 42 patients undergoing total knee arthroplasty. Total blood loss measured at 72 hours was 678 ml in TXA treated group while 1419 ml in the control group. Blood loss on discharge from PACU was 58% reduced in the TXA treated group. they also found that at first postoperative day, Hb concentration, expressed as a fraction of postoperative value was significantly higher in TXA group as compared to control group ( 83% vs. 73% respectively : p< 0.01) that itself reflect the blood loss.

Yamasaki et al. in their study on cement less THR found a reduction in total blood loss in TXA treated group (1349 ± 478 ml) than in the control group (1646 ± 469 ml) (p<0.01). Their postoperative laboratory finding showed that the hemoglobin and hematocrit values on the first, seventh, and fourteenth postoperative days were significantly higher in TXA group that in the control group. In addition, the hemoglobin and hematocrit values in the TXA group
recovered to the first preoperative day level by the fourteenth postoperative day.

This study also demonstrates that transfusion requirements also reduced in the study group. A Meta-analysis of nine randomized control trial reveals that use of TXA in TKR significantly reduces the proportion of patients requiring blood transfusion. In another study by Camarasa Godoy and Alvarez, found similar results. Lozano and colleagues found that only 17.6% patients on TXA received blood transfusion in comparison to 54% in the control group. This is said that TXA increase hypercoagulability and can lead to change of thromboembolic episodes, but we did not face any abnormal finding. Benoni also suggested that TXA does not affect risk of DVT because it inhibits fibrinolysis in the wound not in circulation [23-28].

In conclusion, the present paired study demonstrated that the administration of TXA given preoperatively reduces the blood loss in the first 24 hours by a highly significant degree in patients undergoing surgeries for hip and femoral fractures as well it causes a significant reduction in postoperative anemia and need for transfusion among these patients. This would in turn, help avoid complications related with transfusion of blood and blood products. However, further investigation is necessary to determine the effectiveness [29].
References


22. Meybohm P, Herrmann E, Nierhoff J, Zacharowski K, Aprotinin (2013) may increase mortality in low and intermediate risk but not in high risk cardiac surgical patients compared to tranexamic acid and epsilon-aminocaproic acid—a meta-analysis of randomised and observational trials of over 30,000 patients. PloS One 8: e58009.


